Can preoperative CEA and CA19-9 serum concentrations suggest metastatic disease in colorectal cancer patients? 2017

Milica Stojkovic Lalosevic, and Sanja Stankovic, and Mirjana Stojkovic, and Velimir Markovic, and Ivan Dimitrijevic, and Jovan Lalosevic, and Jelena Petrovic, and Marija Brankovic, and Aleksandra Pavlovic Markovic, and Zoran Krivokapic
Clinic of Gastroenterology and Hepatology, Clinical Center of Serbia, Belgrade, Serbia. drmilicastojkovic@gmail.com.

OBJECTIVE This study was designed to investigate the efficiency of preoperative serum carcinoembryonic antigen (CEA) and carbohydrate cancer antigen (CA19-9) levels for diagnosing synchronous liver metastases and lymph node in colorectal carcinoma (CRC) patients. METHODS A total of 300 patients with histologically diagnosed CRC were included in this study between May 2014 and March 2015. The data were obtained prospectively from patient's medical records: medical history, demographics, tumor location, differentiation (grade), depth of the tumor (T), lymph node metastases (N), distant metastases (M), lymphatics, venous and perineural invasion, and disease stage. Tumor markers were measured with an electrochemiluminescent assay and the reference value was 5ng/ml for CEA and for Ca19-9, 37u/ml. RESULTS There was A high statistically significant difference in the levels of serum CEA and CA19-9 between different disease stages of CRC (P<0.001). Regarding different T stages of CRC, We noticed a significant statistical difference in CEA (stage I 3.76±8.73; II 5.68±17.27, III 7.56±14.81, and IV 70.90±253.23) and CA 19-9 levels (stage I 9.65±11.03, II 9.83±11.09; III 19.58±36.91, and IV 228.9±985.38, respectively). The mean CEA and CA19-9 serum levels were significantly higher in patients with regional lymph nodes involvement (CEA 37.21±177.85 vs 4.79±9.90, CA19-9 119.51±687.71 VS 12.24±17.69, respectively, P<0.05) and in liver metastases (CEA 86.56±277.65 vs. 5.98±12.98, and CA19-9 273.27±1073.46 vs. 4.98±3142, respectively, with P<0.001) in comparison to patients without lymph node involvement and liver metastases. We noticed a cut-off value for lymph nodes involvement, for CEA and CA 19-9, 3.5 ng/mL and 7.5 U/mL, respectively. While, a cut-off value for the presence of synchronous liver metastases of these two markers was 3.5ng/mL AND 5.5 U/mL. CONCLUSIONS Our study showed that tumor makers, CEA and CA19-9, can be used as diagnostic factors regarding the severity of CRC specifically to suggest metastatic disease in CRC.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011300 Preoperative Care Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed) Care, Preoperative,Preoperative Procedure,Preoperative Procedures,Procedure, Preoperative,Procedures, Preoperative
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

Milica Stojkovic Lalosevic, and Sanja Stankovic, and Mirjana Stojkovic, and Velimir Markovic, and Ivan Dimitrijevic, and Jovan Lalosevic, and Jelena Petrovic, and Marija Brankovic, and Aleksandra Pavlovic Markovic, and Zoran Krivokapic
March 1996, Minerva chirurgica,
Milica Stojkovic Lalosevic, and Sanja Stankovic, and Mirjana Stojkovic, and Velimir Markovic, and Ivan Dimitrijevic, and Jovan Lalosevic, and Jelena Petrovic, and Marija Brankovic, and Aleksandra Pavlovic Markovic, and Zoran Krivokapic
June 2001, World journal of gastroenterology,
Milica Stojkovic Lalosevic, and Sanja Stankovic, and Mirjana Stojkovic, and Velimir Markovic, and Ivan Dimitrijevic, and Jovan Lalosevic, and Jelena Petrovic, and Marija Brankovic, and Aleksandra Pavlovic Markovic, and Zoran Krivokapic
June 2014, Hepato-gastroenterology,
Milica Stojkovic Lalosevic, and Sanja Stankovic, and Mirjana Stojkovic, and Velimir Markovic, and Ivan Dimitrijevic, and Jovan Lalosevic, and Jelena Petrovic, and Marija Brankovic, and Aleksandra Pavlovic Markovic, and Zoran Krivokapic
January 2015, International journal of clinical and experimental pathology,
Milica Stojkovic Lalosevic, and Sanja Stankovic, and Mirjana Stojkovic, and Velimir Markovic, and Ivan Dimitrijevic, and Jovan Lalosevic, and Jelena Petrovic, and Marija Brankovic, and Aleksandra Pavlovic Markovic, and Zoran Krivokapic
January 1997, Oncology reports,
Milica Stojkovic Lalosevic, and Sanja Stankovic, and Mirjana Stojkovic, and Velimir Markovic, and Ivan Dimitrijevic, and Jovan Lalosevic, and Jelena Petrovic, and Marija Brankovic, and Aleksandra Pavlovic Markovic, and Zoran Krivokapic
April 2021, Clinical laboratory,
Milica Stojkovic Lalosevic, and Sanja Stankovic, and Mirjana Stojkovic, and Velimir Markovic, and Ivan Dimitrijevic, and Jovan Lalosevic, and Jelena Petrovic, and Marija Brankovic, and Aleksandra Pavlovic Markovic, and Zoran Krivokapic
January 2013, Hepato-gastroenterology,
Milica Stojkovic Lalosevic, and Sanja Stankovic, and Mirjana Stojkovic, and Velimir Markovic, and Ivan Dimitrijevic, and Jovan Lalosevic, and Jelena Petrovic, and Marija Brankovic, and Aleksandra Pavlovic Markovic, and Zoran Krivokapic
April 2005, The Journal of surgical research,
Milica Stojkovic Lalosevic, and Sanja Stankovic, and Mirjana Stojkovic, and Velimir Markovic, and Ivan Dimitrijevic, and Jovan Lalosevic, and Jelena Petrovic, and Marija Brankovic, and Aleksandra Pavlovic Markovic, and Zoran Krivokapic
September 2022, BMC cancer,
Milica Stojkovic Lalosevic, and Sanja Stankovic, and Mirjana Stojkovic, and Velimir Markovic, and Ivan Dimitrijevic, and Jovan Lalosevic, and Jelena Petrovic, and Marija Brankovic, and Aleksandra Pavlovic Markovic, and Zoran Krivokapic
January 1996, The American journal of gastroenterology,
Copied contents to your clipboard!